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ABSTRACT 
 
Background. Lymphangioleiomyomatosis (LAM) is a rare multisystem disease almost exclusively 
affecting women which causes loss of lung function, lymphatic abnormalities and 
angiomyolipomas. LAM occurs sporadically and in people with tuberous sclerosis complex (TSC). 
Loss of TSC gene function leads to dysregulated mTOR signalling. As mTOR is a regulator of lipid 
and nucleotide synthesis, we hypothesised that the serum metabolome would be altered in LAM 
and related to disease severity and activity. 
 
Methods. Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy was used 
to examine the serum metabolome of 79 closely phenotyped women with LAM, including 29 
receiving treatment with an mTOR inhibitor and 43 healthy control women. 
 
Results. Sphingolipid, fatty acid and phospholipid metabolites were associated with FEV1 in 
women with LAM (e.g., behenoyl sphingomyelin adj. p = 8.10 x 10-3). Those with higher disease-
burden scores had abnormalities in fatty acid, phospholipid and lysolipids. Rate of loss of FEV1 
was associated with differences in acyl-carnitine, acyl-glycines, acyl-glutamine, fatty acids, 
endocanbinoids and sphingolipids (e.g., myristoleoylcarnitine adj. p = 0.07). 
In TSC-LAM, rapamycin affected modules of interrelated metabolites which comprised linoleic acid, 
the tricarboxylic acid cycle, aminoacyl-tRNA biosynthesis, cysteine, methionine, arginine and 
proline metabolism. Metabolomic pathway analysis within modules reiterated the importance of 
glycerophospholipid metabolites (adj. p = 0.047). 
 
Conclusions. Women with LAM have altered lipid metabolism. The associations between these 
metabolites, multiple markers of disease activity and their potential biological roles in cell survival 
and signalling, suggest that lipid species may be both disease-relevant biomarkers and potential 
therapeutic targets for LAM. 
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KEY MESSAGES 
 
What is the key question? 
Lymphangioleiomyomatosis (LAM) and Tuberous sclerosis complex (TSC) are monogenic 
diseases resulting in mTOR activation which we predict would alter the metabolic profile of patients 
and confer metabolic advantages to LAM cells. 
 
What is the bottom line? 
Multiple sphingolipid, fatty acid and phospholipid metabolites were associated with disease 
severity, activity and, in subjects with TSC treatment with mTOR inhibitors: suggesting that lipid 
species may be both disease-relevant biomarkers and potential therapeutic targets for LAM. 
 
Why read on? 
This is the first study to comprehensively evaluate the serum metabolome in LAM and consistent 
with recent studies highlighting the role of mTOR in cellular lipid metabolism suggests deranged 
lipid metabolism is of potential relevance to disease pathogenesis in LAM and also highlights 
previously unrecognised differences between those with sporadic and TSC-LAM. 
  
4 
 
 
INTRODUCTION 
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease which almost exclusively affects 
women. Sporadic LAM results from sequential somatic mutations of either TSC1, or more 
commonly TSC2. In patients with tuberous sclerosis complex (TSC-LAM), loss of TSC gene 
function occurs due to a germline mutation followed by loss of heterozygosity. The TSC proteins 
are suppressors of the mechanistic target of rapamycin (mTOR). Loss of TSC function in an as yet 
unidentified precursor cell leads to dysregulated mTOR signalling and the emergence of a clone of 
‘LAM cells’ (1). mTOR is a multiprotein cellular signalling node which assimilates inputs from 
growth factors and cellular nutrient status (2). Constitutive mTOR activation leads to unregulated 
cell proliferation, migration, invasion of the lungs and lymphatics and altered metabolism. In the 
lungs, LAM cells and wild type stromal cells form nodules which together result in the formation of 
lung cysts, recurrent pneumothorax and progressive loss of lung function (3). Involvement of the 
axial lymphatics can result in lymphadenopathy, fluid-filled lymphatic masses and chylous 
collections in the abdomen and thorax. LAM cells also are a component of angiomyolipoma, a 
benign tumour affecting around half of the women with LAM (4). Pharmacological suppression of 
mTOR stabilises lung function, reduces lymphatic complications and angiomyolipoma volume in 
the majority of those treated (5,6). 
 
The rate of disease progression is highly variable. Loss of FEV1 is perhaps the best-characterised 
marker of progression with a mean loss of FEV1 around 80-140 ml/year in most populations 
studied (5,7). However, some patients remain stable for many years whilst others have a rapid 
clinical course requiring lung transplantation. LAM cells express oestrogen and progesterone 
receptors and proliferate and metastasise in response to oestrogen in vitro and in vivo (8,9). 
Consistent with this, loss of FEV1 is accelerated by pregnancy and slows after the menopause 
(7,10). 
 
mTOR signalling is a major regulator of lipid synthesis, nucleotide synthesis and glucose 
metabolism. By regulating the transcription factor sterol responsive element binding protein 
(SREBP) both via S6 kinase and through phosphorylation of Lipin1, the expression of genes 
involved in fatty acid and cholesterol biosynthesis are regulated. By increasing glycolytic enzyme 
expression, mTOR complex 1 (mTORC1) supports cellular growth by modulating the balance 
between oxidative phosphorylation and glycolysis, increasing the activity of the pentose phosphate 
pathway. mTORC1 also promotes the synthesis of purine and pyrimidine nucleotides (11,12). 
 
We, therefore, reasoned that women with LAM would have alterations of the serum metabolome, 
due to the metabolic effects of mTOR activation. Moreover, these metabolomic changes would be 
5 
 
 
related to disease severity and activity. To answer these questions, we analysed the serum 
metabolome of a cohort of closely phenotyped women with LAM. 
 
METHODS 
 
SUBJECTS AND CLINICAL DATA 
Women with LAM were recruited from the National Centre for LAM in Nottingham UK. All subjects 
had LAM defined by current ATS/JRS criteria (13). All had a clinical assessment, including drug 
history, clinical screening for TSC, lung function and CT scanning of the chest and abdomen to 
detect angiomyolipoma and lymphatic involvement. Menopausal status was recorded and subjects 
were considered post-menopausal if they had had a bilateral oophorectomy or were over 50 years 
of age and had not had a period for 24 months. None of the subjects were using systemic hormone 
therapy. The study was approved by the East Midlands Research Ethics Committee (13/EM/0264). 
Control subjects were 43 healthy women over the age of 18 with no prior history of lung disease 
from three metabolomic studies (supplementary table 1). The use of control samples was approved 
by Nottingham University Ethics Committee (approval BT A27 08 2009). All subjects gave written 
informed consent. 
 
Tertiles of percent predicted FEV1 and DLCO at the time of assessment were generated with tertile 
1, the highest, and tertile 3, the lowest, values. Lung function decline was calculated as the loss of 
FEV1 (ΔFEV1, ml/yr) in the period preceding blood sampling. Rate of loss of lung function was 
based on a period of observation of greater than 1 year for all subjects. 
 
To stratify the whole-body burden of LAM, a disease burden score between 0 and 3 was used. 
Subjects were assigned one point for each of (i) more severe lung disease defined by an FEV1 or 
DLCO of < 60% predicted, (ii) the presence of an angiomyolipoma at the time of assessment and 
(iii) the presence of lymphatic involvement visible on imaging (lymphadenopathy, cystic lymphatic 
mass or chylous effusion). 
 
SERUM SAMPLES 
Blood was collected in serum separator tubes and processed immediately from subjects without 
fasting. Samples were allowed to clot for 30 minutes at room temperature, centrifuged at 10,000 G 
for 10 minutes and stored in aliquots at −80°C until analysis. Serum VEGF-D was determined 
using Quantikine ELISA DVED00 (R&D Systems, Abingdon, UK). 
 
SERUM METABOLOMICS 
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Serum metabolomics was performed by Metabolon© (Morrisville, NC). Samples were prepared 
using the MicroLab STAR® system (Hamilton Company). Proteins were precipitated with methanol 
and the resulting extracts analysed by two separate reverse phases (RP)/UPLC-MS/MS methods 
with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with 
negative ion mode ESI, and one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI. 
Controls were analysed with the experimental samples including a pooled matrix sample generated 
from experimental samples, extracted water samples as process blanks and quality control 
standards selected not to interfere with endogenous compounds. Experimental samples were 
randomized across the platform run with quality control samples spaced evenly among the 
injections. 
 
The analysis was performed using Ultrahigh Performance Liquid Chromatography-Tandem Mass 
Spectroscopy (UPLC-MS/MS) using a Waters ACQUITY UPLC and a Thermo Scientific Q-
Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray 
ionization (HESI-II) source and Orbitrap mass analyser operated at 35,000 mass resolution. 
Sample extracts were dried and reconstituted in appropriate solvents. Reconstitution solvents 
contained a series of standards at fixed concentrations to ensure injection and chromatographic 
consistency. Four methods appropriate for different ion types and compounds were used, for all 
identified species including lipids. Raw data were extracted, peak-identified and quality control 
processed. Compounds were identified by comparison to a library of >3,300 commercially 
available purified standard compounds and recurrent unknown entities using the retention 
time/index, mass to charge ratio and chromatographic data. Further details are provided in the 
supplementary methods. 
 
STATISTICAL AND BIOINFORMATIC ANALYSIS 
Full details of the statistical and bioinformatics analysis are presented in the supplementary 
methods. Briefly, normalisation of case and control metabolite samples was performed following 
the workflow described by Shin et al (14) and Krumsiek et al. (15). Each raw metabolite value was 
rescaled to have median 1 to adjust for variation due to instrument run-day tuning differences. 
Missing values were imputed using the KNN-TN method (16). Differential analysis of serum 
metabolites was performed using Limma (17) controlling for the False Discovery Rate (FDR) (18). 
Differential co-expression network analysis was used to detect significant associations between the 
relative abundance of metabolites in differential networks, or modules, between conditions and 
their significance assessed through permutation tests (19). Annotation of metabolites was 
performed using HMDB 4.0 (20) release 2019-01-16. Finally, metabolomic pathway analysis was 
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performed by using MetaboAnalyst 4.0 (21) with significant differential metabolite modules 
detected in the differential network analysis mapped in KEGG pathways. 
 
RESULTS 
 
THE METABOLOME IN LAM 
Seventy-nine women with LAM were studied. The subjects were typical of other reported series: 
having an average age of approximately 50 years at the time of study and had had LAM for an 
average of 13.5 years (table 1). Two-thirds had angiomyolipoma, a quarter had had pneumothorax 
in the past and their mean serum VEGF-D was 1,250 pg/ml. Fifteen per cent had TSC and a third 
were post-menopausal. Twenty-nine were being treated for LAM with rapamycin at the time of the 
study. Although of similar age and BMI (two-sided Wilcoxon signed-rank test p = 0.29 and p = 0.92, 
respectively), those treated with rapamycin tended to have lower values of FEV1 and DLCO (two-
sided Wilcoxon signed-rank test p = 3.9 x 10-4 and p = 4.63 x 10-6, respectively). Further details of 
women with LAM are given in supplementary tables 2 and 3. 
 
After compound identification, quantification and data curation, 1,326 serum metabolites were 
identified from 122 individuals. Metabolites spanned a wide range of biochemical classes or super-
pathways including 183 Amino Acid (13.8%), 24 Carbohydrate (1.8%), 21 Cofactors and Vitamins 
(1.6%), 10 Energy (0.8%), 471 Lipid (35.5%), 32 Nucleotide (2.4%), 79 Peptide (6%) and 115 
Xenobiotics (8.7%) and a remaining group of 391 untargeted metabolites (29.5%). A heatmap of 
the log-transformed corrected metabolites and super-pathways levels with the groups considered 
in the analysis is presented in figure 1.  
 
We examined how individual metabolites varied with the presence or absence of LAM. Using an 
FDR of 10%, there were no differences in the abundance of individual metabolites between women 
with LAM who had not received rapamycin and healthy control women (supplementary table 4). 
Control metabolomic profiles were quite variable. Hierarchical clustering showed that there was no 
segregation between control samples from the current study and companion metabolites studies 
(supplementary figure 1). Variation was lower in women with LAM and differences in the metabolic 
profile were observed when women with LAM were stratified according to menopausal status, lung 
function, disease burden and disease activity (table 2). 
 
ASSOCIATION OF METABOLIC CHANGES WITH DISEASE SEVERITY AND ACTIVITY 
To test the hypothesis that dysregulation of the metabolome was related to disease severity and 
activity, individuals with LAM were stratified according to the severity of their lung disease, the 
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whole-body burden of LAM and rate of loss of FEV1. As we suspected that mTOR inhibition would 
affect the metabolome, we restricted this analysis to the 50 subjects who had not received 
rapamycin. Subjects were grouped into tertiles of FEV1 and DLCO (tertile 1 highest values, tertile 3 
lowest, see supplementary table 3). Comparing tertiles 1 and 2 applying a 10% FDR, reductions 
were seen in sphingolipids (behenoyl sphingomyelin (adj. p = 8.10 x 10-3), lignoceroyl 
sphingomyelin (adj. p = 8.10 x 10-3), lactosyl-N-behenoyl-sphingosine (adj. p = 3.06 x 10-2), 
tricosanoyl sphingomyelin (adj. p = 6.23 x 10-2) and palmitoyl dihydrosphingomyelin (adj. p = 9.75 x 
10-2)), fatty acids (eicosenoylcarnitine (adj. p = 8.68 x 10-2)), phospholipids (1-palmityl-2-stearoyl-
GPC (adj. p = 8.10 x 10-3)) and pantothenate (adj. pantothenate (adj. p = 9.75 x 10-2)), see 
supplementary figure 2. Full details are presented in supplementary table 5. There were no 
significant associations between metabolites and DLCO (table 2). 
 
To examine the relationship between the metabolome and the whole body burden of LAM, we then 
stratified subjects by a score that reflected the presence of disease in the lungs, lymphatic tissue 
and angiomyolipomas (score 0 lowest disease burden, score 3 highest disease burden, see 
supplementary table 3). Those with the highest disease-burden score had abnormalities in four 
fatty acid, four phospholipid and one lysolipid metabolite (supplementary table 5). Stearoylcholine, 
lineloylcholine, palmitoylcholine, oleylcholine, docosahexaenoylcholine, arachadonycholine, 
eicosapentaenoylcholine, dihomo-linolenoyl-choline and 2-stearoyl-GPI (18:0) differed in 
abundance across levels of disease burden, tending to be lower in more extensive disease (figure 
2 and supplementary figure 3). Although the same pathways were associated with both lung 
function and disease burden, the individual metabolites within these pathways differed 
(supplementary table 5). 
 
Rate of loss of FEV1 was used as a measure of disease activity. Subjects were divided into tertiles, 
with 1 being the lowest (best) rate of FEV1 loss. Changes in abundance of 22 metabolites, at an 
FDR of 10% were observed between those with the lowest ΔFEV1 in tertile 1 and those with the 
fastest ΔFEV1 in tertile 3 (figure 3). Again, metabolites associated with ΔFEV1 were almost all lipid-
based comprising eight acyl-carnitine, one acyl-glycine, one acyl-glutamine, five fatty acid, three 
endocanbinoid and two sphingolipids (table 3 and supplementary table 5). 
 
METABOLIC CHANGES POST-MENOPAUSE 
Several studies have reported that the mean rate of loss in FEV1 is slower in post-menopausal 
than pre-menopausal women with LAM (7,10). We therefore compared the metabolome of the 33 
pre- and 17 post-menopausal women who had not been treated with rapamycin. In post-
menopausal women, as expected, 18 sex steroid metabolites were altered (supplementary table 4 
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and supplementary figure 5). Metabolomic pathway analysis identified that menopausal status was 
associated with significant enrichment of the steroid hormone biosynthesis pathway 
(supplementary figure 6). Also, levels of 14 acyl-carnitine, one acyl-glycine, one acyl-glutamine, 12 
phospholipids, five fatty acids, five diacylglycerols and two secondary bile acid metabolites were 
altered (supplementary table 4). 
 
EFFECT OF RAPAMYCIN ON THE SERUM METABOLOME 
Women with sporadic LAM treated with rapamycin had similar metabolomic profiles to those not 
treated with rapamycin. In contrast, in those with TSC-LAM, rapamycin affected a network of 
interrelated metabolites whose significance was assessed by empirical p-value < 0.1. Although no 
individual metabolites significantly differed in abundance (supplementary figure 4), changes in 
related groups of metabolites were identified as differential co-expression networks or ‘modules’. 
The modules, arbitrarily described by colours, are described in detail in supplementary table 6. 
These modules were not detected if a co-expression network analysis was performed separately 
on TSC-LAM samples with and without rapamycin treatment (supplementary figure 7). The 
relationship between modules, suggests these metabolites are either interdependent or affected in 
a similar manner by mTOR inhibition (figure 4). Individual modules (blue, tan and magenta) were 
also significantly negatively associated with FEV1, while FEV1, a measure of disease activity, was 
significantly positively correlated with the blue module. These associations were not seen in 
subjects treated with rapamycin (figure 5B), suggesting they are downstream of mTORC1.  
Metabolomic pathway analysis of the individual modules again shows a significant contribution 
from glycerophospholipid metabolites that are altered by treatment with rapamycin (figure 5A and 
supplementary figure 8). 
 
DISCUSSION 
This study is the first comprehensive examination of the serum metabolome in a large cohort of 
women with LAM. Sphingolipid and fatty acid metabolism were associated with the severity of lung 
disease, total body burden of LAM and disease activity defined by the rate of loss of FEV1. 
Comparison of mTOR inhibitor treated and untreated women showed changes in metabolite 
networks incorporating glycerophospholipid metabolites in subjects with TSC-LAM but not sporadic 
LAM. These findings are likely to reflect the altered metabolism of the LAM cell with metabolites 
related to disease activity and severity. 
 
We observed that FEV1, a measure of airflow limitation, was related to sphingolipid and fatty acid 
metabolism, although this was not a simple relationship with the greatest abnormalities seen in 
those with moderate impairment (tertile 2). Airflow limitation in LAM is thought to be due to loss of 
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elastic recoil resulting from parenchymal destruction and these metabolomic alterations may reflect 
the amount of parenchymal involvement. However, as we observed that the same metabolomic 
pathways were also related to the rate of loss of FEV1, a measure of disease activity, it is also 
possible that FEV1 tertile 2 contained those with the most active disease, both in terms of disease 
progression and mTOR driven metabolic changes. Subjects with better-preserved FEV1 (tertile 1) 
may have less active disease and those with the most advanced disease (tertile 3) may have 
reached a ‘burned out’, less metabolically active stage. This idea is supported by the strong linear 
association between acyl-carnitine fatty acid and sphingolipid metabolism with the rate of FEV1 
loss, suggesting changes in the lipidome are associated with both disease extent and activity. 
 
We reasoned that at least some of the metabolic changes observed would be related to the 
number of LAM cells in the body. The disease’s clinical phenotype, and hence LAM cell burden, is 
variable with some having extensive lymphatic involvement or large angiomyolipomas and others 
having only lung disease. It is not possible to accurately determine the ‘whole-body burden’ of LAM 
cells, particularly as some organ involvement is likely to be sub-clinical (22). We therefore, used a 
simple score comprising mild or more advanced lung disease, the presence of angiomyolipoma 
and lymphatic involvement visible by clinical imaging. As we predicted, this ‘disease burden’ score 
was associated with the degree of metabolic abnormality in acyl-choline fatty acid metabolism and 
phospholipids with the same group of 10 metabolites significantly different between all groups with 
the largest differences in those with the greatest disease burden. 
 
The observations that LAM is one of the most female-specific diseases described, that rate of loss 
of FEV1 is lower in postmenopausal women (7,10), can be exacerbated by pregnancy (23,24) and 
occurs earlier in those exposed to oestrogen containing contraceptives (25), suggest that LAM is 
likely to be oestrogen driven and we had expected the metabolome to reflect increased disease 
activity in pre-menopausal women. As anticipated, there were widespread changes in sex steroid 
metabolism between pre- and post-menopausal women with LAM. We also observed changes in 
phospholipid and acyl-carnitine fatty acid metabolism. Whilst it is tempting to speculate this change 
is related to reduced disease activity as a result of lower oestrogen levels, the menopause in 
healthy women is also associated with changes in acyl-carnitine, fatty acid and 
lysophosphatidylcholine metabolism (26) and we are unable to relate the changes observed here 
to a specific set of processes. 
 
The molecular defect in the TSC proteins and the impressive reduction in lung function decline 
during mTOR inhibitor therapy suggests that mTOR activation is the key driver of LAM and TSC 
(1,5). In our study, the metabolic abnormalities associated with disease extent and activity are 
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almost exclusively comprised of lipids, particularly sphingolipids, phospholipids and acyl-carnitine 
fatty acids, reflecting metabolic processes downstream of mTOR. As an investigation in a 
monogenic disease characterised by mTOR dysregulation; our study provides a translational 
link between this basic mTOR biology, LAM and other diseases in which mTOR is activated. 
The changes observed represent a metabolic signature of increased fatty acid synthesis and 
uptake which is also a characteristic of cancer cells (27,28). Glycerophospholipid and sphingolipid 
metabolites are also associated with airflow obstruction in patients with COPD, whilst mTOR can 
be activated to some degree in COPD it is also possible these changes are a response to tissue 
damage (29). mTORC1 and 2 stimulate expression and processing of SREBP1 and suppress its 
negative regulator LIPIN1. SREBP1 is a transcription factor responsible for the expression of 
the fatty acid synthases, ATP citrate lyase, fatty acid synthase, acetyl-CoA carboxylase 1 and 
stearoyl-CoA desaturase. In addition, mTORC1 further stabilises these gene transcripts to 
enhance fatty acid synthesis and enhances fatty acid uptake via CD38. Lipidomic profiling of 
TSC2 null murine fibroblasts has similarly shown an increase in multiple lipid species including 
phosphatidylcholine, lysophosphatidylcholines, phospholipids, sphingomyelins and triacylglycerols 
(30). Inhibition of mTOR signalling with rapamycin in TSC2 null murine fibroblasts did not 
suppress the overproduction of most lipid species, whereas downregulation of SREBP1 did, 
perhaps as SREBP1 is known to be only partially rapamycin sensitive (31). These observations 
are consistent with our findings showing that serum lipid abnormalities were only affected by 
rapamycin therapy in subjects with TSC where although groups of metabolites, or modules, 
were altered by rapamycin, only glycerophospholids were consistently differentially abundant in 
those receiving rapamycin. Also consistent with a role for mTORC1 in metabolism was the 
observation that the associations between metabolite networks, lung function and disease 
activity were not seen in women with LAM who were being treated with rapamycin. 
 
The LAM cell, analogous to a cancer cell, is likely to use altered lipid metabolism to support cell 
membrane synthesis: as constituents of membrane lipid rafts, saturated and monounsaturated 
phospholipids, potentially protect cancer cells from oxidative damage by reducing lipid peroxidation 
(32). As second messengers, lipids, including sphingosine 1-phosphate, promote cell 
proliferation and migration and in turn feedback to activate mTOR signalling (28). Depletion of 
SREBP1 and 2 reduces monounsaturated fatty acids, resulting in mitochondrial dysfunction, the 
accumulation of reactive oxygen species and endoplasmic reticulum stress (33). Inhibitors of 
various lipid synthetic enzymes are currently in clinical trials for cancer and may also have 
therapeutic potential in conjunction with mTOR inhibitors for LAM and TSC. 
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The metabolomic platform used identifies metabolites based upon a combination of three 
MS/MS criteria referenced against library data of over 3,300 purified standards. Whilst no 
targeted assays are performed the approach has been extensively applied and validated (34). 
We were surprised to observe that after statistical corrections, healthy women and those with 
LAM did not have different metabolic profiles. The healthy control samples were variable, with 
no apparent clustering dependent upon the source of the control sample. In addition, within 
women with LAM, significant metabolic changes in response to rapamycin were only observed 
in patients with TSC-LAM. Whilst TSC and sporadic LAM have the same underlying molecular 
abnormality (35), those with TSC-LAM may have larger changes in lipid metabolism, due to 
other TSC related tumours and perhaps widespread haplo-insufficiency for TSC. 
 
LAM is a rare disease with a variable clinical phenotype and despite this being the largest 
metabolic analysis in LAM to date, the relatively small sample size reduces the statistical power to 
detect differential metabolites which may account for some of the unexpected results we have 
observed: in particular between healthy women and those with LAM not treated with rapamycin. 
Possible approaches would be to define a more liberal level of significance or FDR although this 
may increase false positive observations. Alternatively, pooling ‘similar’ metabolites (36), such as 
those that belong to the same KEGG pathway, could increase power. 
 
In conclusion, we have performed the largest comprehensive metabolomic study in women with 
LAM to date and have demonstrated multiple abnormalities in lipid metabolism, particularly, 
sphingo- and phospho-lipids, and the fatty acids acyl-carnitine, acyl-choline and acyl-glycine. 
These changes are poorly responsive to rapamycin, the only disease modifying therapy for LAM 
and are likely to contribute to LAM cell growth, survival and resulting lung damage. The 
associations between these metabolites, multiple markers of disease activity and their potential 
roles in cell survival and signalling, suggest that lipid species may be both disease-relevant 
biomarkers and potential therapeutic targets. 
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TABLES 
 
Table 1. Patient characteristics. 
 
 All subjects 
No rapamycin 
treatment 
Rapamycin 
treated 
Sample size 79 50 29 
Age (yrs) 49.6 (11.1) 50.6 (10.9) 48.0 (11.5) 
BMI (kg/m2) 25.6 (6.1) 25.6 (6.2) 25.5 (6.1) 
Disease duration (yrs) 13.5 (11.0) 13.9 (11.1) 12.8 (11.0) 
Post menopause (%) 33 22 11 
Phenotype 
TSC (%) 15 14 17 
Angiomyolipoma (%) 65 72 52 
Lymphatic involvement (%) 18 16 21 
Pneumothorax (%) 25 30 17 
Serum VEGF-D (pg/ml) 1,250 (1,201) 1,287 (1,165) 1,182 (1,284) 
Lung function 
FEV1 (% predicted)  62 (21) 69 (21) 50 (17) 
DLCO (% predicted)  55 (16) 60 (16) 43 (11) 
pre-treatment ΔFEV1 (ml/yr) -77 (168) -54 (91) -113 (241) 
 
Group means (standard deviation) of subjects stratified by treatment with rapamycin. BMI = Body 
mass index; TSC = tuberous sclerosis complex; VEGF-D = vascular endothelial growth factor-D; 
FEV1 = forced expiratory volume in one second (ml); DLCO = diffusing capacity of the lung for 
carbon monoxide (ml/min/kPa); ΔFEV1 = annual decline in forced expiratory volume (ml/yr). 
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Table 2. Number of differential metabolites identified. 
 
Groups 
Age covariate removed Age covariate not removed 
< 0.10% 
FDR 
< 0.10% FDR & 
|log2 FC| > 0.4 
< 0.10% 
FDR 
< 0.10% FDR & 
|log2 FC| > 0.4 
LAM untreated vs healthy women 0 0 - - 
LAM pre-menopause untreated vs 
LAM post-menopause untreated 
- - 68 40 
mTOR inhibition     
TSC-LAM untreated vs TSC-LAM 
rapamycin treated 
0 0 - - 
Sporadic LAM untreated vs 
sporadic LAM rapamycin treated 
0 0 - - 
TSC-LAM untreated vs sporadic 
LAM untreated 
1 0 - - 
TSC-LAM rapamycin treated vs 
sporadic LAM rapamycin treated 
9 2 - - 
FEV1     
T1 vs T2  11 0 - - 
T2 vs T3  0 0 - - 
T1 vs T3  0 0 - - 
T1 vs T2 & T3 0 0 - - 
DLCO     
T1 vs T2  0 0 - - 
T2 vs T3  0 0 - - 
T1 vs T3  0 0 - - 
T1 vs T2 & T3 0 0 - - 
Disease burden     
S0 vs S1 1 0 - - 
S1 vs S2 0 0 - - 
S2 vs S3 32 20 - - 
S0 vs S1, S2 & S3 10 9 - - 
Disease activity     
ΔFEV1 T1 vs T2  0 0 - - 
ΔFEV1 T2 vs T3  3 2 - - 
ΔFEV1 T1 vs T3  22 2 - - 
ΔFEV1 T1 vs T2 & T3 3 0 - - 
 
Number of differential metabolites at 10% FDR threshold and at 10% FDR threshold with |log2 Fold 
Change (FC)| > 0.4 after removing the effect of sex, BMI, ethnicity, study covariate (only in ‘LAM 
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untreated vs healthy women’ contrast) and experimental run day and excluding metabolites of 
unknown identity and the ‘Xenobiotics’ super-pathway. TSC = tuberous sclerosis complex; VEGF-
D = vascular endothelial growth factor-D (pg/ml); FEV1 = forced expiratory volume in one second 
(ml); ΔFEV1 = annual decline in forced expiratory volume (ml/yr). OBD = overall disease burden 
score; T = tertile, 1 highest, 3 lowest. For group definitions, see supplementary table 3. Full results 
are presented in supplementary tables 4 and 5. 
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Table 3. Lipid mediators associated with rate of loss of FEV1. 
 
Biochemical name Sub-pathway 
ΔFEV1 T1 vs T2 ΔFEV1 T2 vs T3 ΔFEV1 T1 vs T3 ΔFEV1 T1 vs T2 & T3 
FC Adj. p FC Adj. p FC Adj. p FC Adj. P 
myristoleoylcarnitine (C14:1)* Acyl carnitine -0.107 0.998 -0.338 0.165 -0.445 0.070 -0.377 0.812 
laurylcarnitine (C12) Acyl carnitine -0.149 0.998 -0.266 0.256 -0.415 0.070 -0.376 0.812 
palmitoleoylcarnitine (C16:1)* Acyl carnitine -0.068 0.998 -0.243 0.160 -0.311 0.070 -0.253 0.812 
oleoyl ethanolamide Endocanbinoid -0.022 0.998 -0.191 0.154 -0.213 0.070 -0.152 0.859 
N-palmitoylglycine Acyl glycine -0.017 0.998 -0.164 0.154 -0.182 0.070 -0.107 0.859 
palmitoyl ethanolamide Endocanbinoid -0.019 0.998 -0.151 0.154 -0.170 0.070 -0.103 0.859 
sphingomyelin (d18:2/24:1, d18:1/24:2)* Sphingolipid 0.018 0.998 -0.153 0.047 -0.135 0.070 -0.080 0.859 
ximenoylcarnitine (C26:1)* Acyl carnitine -0.148 0.968 -0.056 0.705 -0.204 0.073 -0.294 0.039 
adrenate (22:4n6) Fatty acid -0.036 0.998 -0.295 0.160 -0.331 0.078 -0.229 0.859 
dihomolinoleate (20:2n6) Fatty acid -0.028 0.998 -0.293 0.160 -0.321 0.078 -0.220 0.859 
docosapentaenoate (n6 DPA; 22:5n6) Fatty acid -0.006 0.998 -0.246 0.154 -0.252 0.078 -0.192 0.859 
dihomolinolenate (20:3n3 or 3n6) Fatty acid -0.024 0.998 -0.177 0.160 -0.201 0.078 -0.153 0.859 
oleoylcarnitine (C18) Acyl carnitine -0.076 0.998 -0.101 0.371 -0.176 0.078 -0.178 0.751 
sphingomyelin (d18:1/24:1, d18:2/24:0)* Sphingolipid -0.034 0.998 -0.068 0.275 -0.102 0.078 -0.094 0.858 
allantoin Purine 0.190 0.263 -0.011 0.943 0.179 0.078 0.308 0.006 
hexanoylglutamine Acyl glutamine -0.056 0.998 -0.328 0.175 -0.384 0.082 -0.226 0.859 
suberoylcarnitine (C8-DC) Acyl carnitine -0.038 0.998 -0.323 0.160 -0.361 0.082 -0.206 0.859 
docosadienoate (22:2n6) Fatty acid -0.028 0.998 -0.245 0.160 -0.272 0.082 -0.173 0.859 
linoleoyl ethanolamide Endocanbinoid -0.031 0.998 -0.165 0.175 -0.196 0.082 -0.142 0.859 
palmitoylcarnitine (C16) Acyl carnitine -0.062 0.998 -0.092 0.371 -0.154 0.085 -0.133 0.859 
gamma-glutamylalanine 
Gamma-glutamyl 
amino acid 
0.071 0.998 0.106 0.371 0.178 0.085 0.121 0.859 
eicosenoylcarnitine (C20:1)* Acyl carnitine -0.097 0.998 -0.068 0.565 -0.164 0.097 -0.179 0.751 
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Lipid mediators associated with rate of change of FEV1 (ΔFEV1) (ml/yr) at 10% FDR. Metabolites are ranked by significance and -log2 Fold 
Change comparing the largest difference, Tertile 1 (T1, lowest (best) ΔFEV1) with T3 (greatest (worst) ΔFEV1). Adj. p = adjusted p-value, FC = -
log2 Fold Change. Red and blue cells indicate metabolites that are significantly different between conditions at 10% FDR with |log2 FC| > 0.4 
and metabolites significant at 10% FDR with |log2 FC| < 0.4, respectively. *Compounds identified without confirmation by a standard. Volcano 
plot of ΔFEV1 T1 vs T3 is shown in figure 3. Full results are presented in supplementary table 5. 
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FIGURE LEGENDS 
 
Figure 1. Heatmap of log-transformed metabolite levels after correcting for confounding 
factors. Hierarchically clustered metabolites (horizontal) stratified by super-pathway and 
participants of the study (vertical) stratified by healthy controls and women with LAM pre- and post-
menopause with and without rapamycin treatment (greyscale colour code); patients with TSC-LAM 
and sporadic LAM with and without rapamycin treatment (red scale); FEV1 = forced expiratory 
volume in one second (blue scale); DLCO = diffusing capacity of the lung for carbon monoxide 
(green scale); overall disease burden (orange scale); disease activity based on ΔFEV1 = annual 
decline in forced expiratory volume (ml/yr); T = tertile, 1 highest, 3 lowest. S = score, 0 lowest, 3 
highest. For group definitions, see supplementary table 3. 
 
Figure 2. Volcano plot of fatty acids and phospholipids across overall disease burden. 
Significantly different metabolites at 10% False Discovery Rate (FDR) (y-axis) with |log2 Fold 
Change (FC)| > 0.4 (x-axis) in patients not treated with rapamycin between overall disease burden 
score S0 (lowest, n = 8) and scores S1 (n = 17), S2 (n = 23) and S3 (highest, n = 2) (for group 
definitions, see supplementary table 3). Red, blue, green and grey dots indicate metabolites that 
are significantly different between conditions at 10% FDR with |log2 FC| > 0.4, metabolites 
significant at 10% FDR with |log2 FC| < 0.4, non-significant at 10% FDR with |log2 FC| > 0.4 and 
overall NS = non-significant, respectively. *Compounds identified without confirmation by a 
standard. Full results are presented in supplementary table 5. 
 
Figure 3. Volcano plot of metabolic changes in patients with rate loss of FEV
1
. Significantly 
different metabolites at 10% False Discovery Rate (FDR) (y-axis) with |log
2
 Fold Change (FC)| > 
0.4 (x-axis) in patients not treated with rapamycin with ΔFEV1
1
 T1 (n = 13) and ΔFEV
1
 T3 (n = 12) 
(for group definitions, see supplementary table 3). Red, blue and grey dots indicate metabolites 
that are significantly different between conditions at 10% FDR with |log
2
 FC| > 0.4, metabolites 
significant at 10% FDR with |log
2
 FC| < 0.4 and overall NS = non-significant, respectively. * 
Denotes compounds identified without confirmation by a standard. Full results are provided in 
supplementary table 5. 
 
Figure 4. Differential co-expression network analysis after mTOR inhibitor treatment. (A) 
Dendrogram showing clustering of differential co-expressed metabolites (modules) based on TSC-
LAM samples without (n = 5) and with (n = 7) mTOR inhibitor treatment (for group definitions, see 
supplementary table 3). Top bar: metabolites with |log2 FC| > 0.4 (green); bottom colour bar: 
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colours identify 15 modules generated by unsupervised hierarchical clustering. (B) Comparative 
correlation heat map (red corresponds to positive correlations, blue to negative correlations). The 
upper diagonal matrix shows the correlation between pairs of metabolites in the TSC-LAM 
rapamycin group while the lower diagonal matrix shows the correlation between pairs of 
metabolites in the TSC-LAM untreated group. Modules are identified in the heatmap by colour-
coded squares and on the top by a colour bar. (C) Significance of the identified differential co-
expressed metabolites and covariation between modules (empirical p-values inside each modules 
pair). Modules are identified on the top by a colour bar with number of metabolites in each module. 
 
Figure 5. Pathway analysis of modules affected by mTOR inhibition. Differential co-expressed 
metabolites (modules) pathway analysis and correlation with clinical phenotypes in the TSC-LAM 
samples without (n = 5) and with (n = 7) rapamycin treatment (for group definitions, see 
supplementary table 3). (A) Scatterplots depicting -log10 p-values of the metabolomic pathway 
analysis (y-axis) and impact values from topology pathway analysis (x-axis). For each significant 
module (empirical p-value < 0.1) with at least one significant pathway, metabolomic pathways 
detected at 10% Holm–Bonferroni correction are highlighted (full results are presented in 
supplementary table 6). Modules are identified by the colour bar, dot sizes are proportional to the 
number of altered metabolites within the pathway. (B) Table of correlations and p-values for 
studying the relationships between modules ‘eigen-metabolites’ (rows) and selected clinical traits 
(columns) in TSC-LAM samples without (left) and with (right) rapamycin treatment. Significant 
Spearman correlations at 10% nominal level of significance and corresponding p-values are 
reported inside the tables. 
